Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/31/2025

Rasburicase for Tumor Lysis Syndrome

Introduction to Rasburicase

  • Rasburicase is a recombinant urate oxidase enzyme that rapidly converts existing uric acid to allantoin, which is 5-10 times more soluble in urine than uric acid, making it a highly effective treatment for hyperuricemia associated with tumor lysis syndrome, as recommended by the European Society for Medical Oncology 1, 2

Biochemical Properties and Mechanism of Action

  • The gene encoding urate oxidase was cloned from Aspergillus flavus and expressed in a modified strain of Saccharomyces cerevisiae, allowing production and purification of the recombinant enzyme, with a molecular mass of about 34 kDa, according to the American Society of Clinical Oncology 3
  • Rasburicase catalyzes the enzymatic oxidation of poorly soluble uric acid into an inactive and more soluble metabolite (allantoin), which is readily excreted by the kidneys, as stated by the National Comprehensive Cancer Network 1

Clinical Applications

  • Rasburicase is primarily indicated for the initial management of plasma uric acid levels in patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anticancer therapy expected to result in tumor lysis syndrome, as recommended by the American Society of Hematology 4
  • It is particularly valuable in high-risk patients, including those with bulky disease, high-grade lymphomas, acute lymphoblastic leukemia, and elevated LDH, according to the European Society for Medical Oncology 5

Dosing and Administration

  • Chemotherapy can typically be started 4 hours after initiation of rasburicase treatment, as stated by the Journal of Clinical Oncology 3

Efficacy

  • Rasburicase rapidly decreases plasma uric acid levels, with reductions of 86% observed within 4 hours of the first dose compared to only 12% with allopurinol, as reported by the American Society of Clinical Oncology 3, 6
  • Rasburicase treatment is associated with significant decreases in serum creatinine levels and improvements in renal function, according to the National Kidney Foundation 3

Safety and Adverse Effects

  • Common adverse reactions include hypersensitivity reactions, hemolysis in patients with G6PD deficiency, and methemoglobinemia, as warned by the FDA 3, 7
  • Rasburicase-specific antibodies may develop in some patients, as reported by the Journal of Clinical Oncology 3

Advantages Over Allopurinol

  • Rasburicase degrades existing uric acid, while allopurinol only prevents new formation by inhibiting xanthine oxidase, as explained by the European Society for Medical Oncology 1, 2
  • Rasburicase acts more rapidly than allopurinol, with significant reductions in uric acid levels within hours rather than days, as stated by the American Society of Clinical Oncology 3, 6

Clinical Considerations

  • Allopurinol should not be administered concurrently with rasburicase to avoid xanthine accumulation and lack of substrate for rasburicase, as recommended by the American Society of Clinical Oncology 2
  • Urine alkalinization is not recommended in patients receiving rasburicase therapy, as stated by the National Comprehensive Cancer Network 2
  • Rasburicase should be used with caution in patients with a history of allergic reactions, as warned by the FDA 3, 7

Safety Considerations for Rasburicase Use

Drug Interactions

  • Rasburicase must not be co‑administered with xanthine oxidase inhibitors (e.g., allopurinol, febuxostat) because inhibition of xanthine oxidase leads to accumulation of xanthine and hypoxanthine, which can precipitate in renal tubules and cause obstructive uropathy. 8

Specimen Handling

  • To prevent artifactual reductions in measured uric acid, blood samples drawn for rasburicase monitoring should be placed on ice immediately and analyzed within 4 hours, as the enzyme continues to oxidize uric acid at room temperature. 8

Contraindications

  • Rasburicase is contraindicated in individuals with glucose‑6‑phosphate dehydrogenase (G6PD) deficiency, since the hydrogen peroxide generated during uric‑acid oxidation can precipitate severe hemolysis and methemoglobinemia. 8